Substance Use and Human Health: Risks and Health Consequences
Substance use disorders represent one of the most significant contributors to preventable morbidity and mortality in the United States, intersecting with physical health, mental health, and social determinants across every demographic group. The health consequences of substance use range from acute toxicity and organ damage to chronic neurological remodeling, with effects that compound across the lifespan. This page describes the clinical and public health dimensions of substance use, including definitional frameworks, physiological mechanisms, high-risk scenarios, and the thresholds that distinguish use from disorder.
Definition and scope
Substance use, as formally defined by the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5), encompasses a spectrum from hazardous use through substance use disorder (SUD), with severity classified as mild, moderate, or severe based on 11 diagnostic criteria including craving, loss of control, and continued use despite harm. The Substance Abuse and Mental Health Services Administration (SAMHSA) operates as the primary federal authority for SUD classification, treatment standards, and public health surveillance in the United States.
The scope of regulated substances relevant to human health includes:
- Alcohol — the most widely used psychoactive substance in the US; associated with liver disease, cardiovascular damage, and at least 95,000 deaths per year (CDC, Alcohol-Related Disease Impact Application)
- Tobacco and nicotine products — causally linked to at least 480,000 deaths annually in the US (CDC, Smoking and Tobacco Use)
- Opioids — including prescription pain relievers, heroin, and synthetic opioids such as fentanyl; responsible for more than 80,000 overdose deaths in 2021 (CDC, Drug Overdose Surveillance)
- Stimulants — cocaine, methamphetamine, and prescription stimulants; associated with cardiovascular events and psychiatric sequelae
- Cannabis — federally classified as Schedule I under the Controlled Substances Act (21 U.S.C. § 812), though legal under state law in 24 states as of 2024 (NCSL, State Medical Cannabis Laws)
- Sedative-hypnotics and benzodiazepines — associated with respiratory depression, dependence, and fatal overdose when combined with opioids
Substance use is distinct from substance use disorder. Hazardous or harmful use refers to patterns that increase risk of health consequences without meeting full diagnostic criteria. The broader framework of human health treats SUD as a chronic, relapsing medical condition with neurobiological underpinnings — not a moral failing.
How it works
Substances that produce dependence share a common pharmacological pathway: activation of the brain's mesolimbic dopamine system, specifically the nucleus accumbens. This circuit, sometimes called the "reward pathway," is hijacked by psychoactive substances to produce supraphysiological dopamine release — in some cases 2 to 10 times the level produced by natural rewards (National Institute on Drug Abuse, NIDA, Drug Facts).
Repeated exposure produces two neuroadaptive changes:
- Tolerance — the brain downregulates dopamine receptor density and sensitivity, requiring larger doses to achieve equivalent effect
- Dependence — neurochemical homeostasis shifts such that absence of the substance produces withdrawal symptoms, which may be mild (cannabis) to life-threatening (alcohol, benzodiazepines)
Beyond reward circuitry, chronic substance use affects:
- Prefrontal cortex function — impairing executive decision-making, impulse control, and risk assessment
- Amygdala reactivity — heightening stress responses and cue-triggered cravings
- Hippocampal memory consolidation — disrupting associative learning and producing substance-linked conditioned responses
Organ-level damage varies by substance class. Alcohol is hepatotoxic, causing fatty liver, alcoholic hepatitis, and cirrhosis with sustained heavy use. Tobacco combustion products are carcinogenic across the aerodigestive tract. Methamphetamine produces neurotoxic loss of dopamine and serotonin terminals in the striatum and prefrontal cortex. Opioids suppress brainstem respiratory drive, the primary mechanism of fatal overdose.
The interaction between substance use and stress physiology is bidirectional: stress is a major relapse trigger, and substance use dysregulates the hypothalamic-pituitary-adrenal (HPA) axis, elevating baseline cortisol and lowering stress tolerance over time.
Common scenarios
Substance use intersects with human health in predictable high-risk configurations:
Polysubstance use: Concurrent use of alcohol and benzodiazepines, or opioids and benzodiazepines, produces synergistic central nervous system depression. The FDA issued a black-box warning (FDA Drug Safety Communication, 2016) for opioid-benzodiazepine combinations citing respiratory depression and death.
Adolescent initiation: The developing brain remains structurally immature through approximately age 25. Substance initiation before age 18 is associated with a 4- to 7-fold higher lifetime risk of SUD compared to initiation after age 21 (NIDA).
Co-occurring mental health disorders: An estimated 21.5 million adults in the US had co-occurring SUD and mental illness in 2021 (SAMHSA, National Survey on Drug Use and Health 2021). The relationship is bidirectional: psychiatric conditions increase vulnerability to substance use, and substances can precipitate or worsen psychiatric symptoms.
Prescription opioid transition: Approximately 80% of people who use heroin report initiating opioid use via prescription opioids (NIDA).
Pregnancy: Prenatal substance exposure produces fetal alcohol spectrum disorders (FASDs), neonatal opioid withdrawal syndrome (NOWS), and preterm birth, each with distinct pediatric health trajectories.
Decision boundaries
The clinical and public health distinction between substance use, hazardous use, and SUD determines what interventions are indicated:
| Classification | Criteria | Standard Response |
|---|---|---|
| Low-risk or moderate use | Consumption within established guidelines; no impairment or harm | Brief intervention, health education |
| Hazardous or harmful use | Exceeds recommended thresholds; some associated harm; no DSM-5 SUD criteria met | Screening, Brief Intervention, Referral to Treatment (SBIRT) |
| Mild SUD | 2–3 DSM-5 criteria present | Outpatient counseling, medication evaluation |
| Moderate SUD | 4–5 DSM-5 criteria present | Intensive outpatient or partial hospitalization |
| Severe SUD | 6+ DSM-5 criteria present | Residential treatment, medically managed withdrawal, medication-assisted treatment (MAT) |
SAMHSA recognizes three FDA-approved medications for opioid use disorder (OUD): methadone, buprenorphine, and naltrexone. For alcohol use disorder (AUD), FDA-approved pharmacotherapy includes naltrexone, acamprosate, and disulfiram. Medication-assisted treatment significantly reduces overdose mortality — buprenorphine treatment is associated with a 50% reduction in overdose death risk (SAMHSA, Medications for Opioid Use Disorder, TIP 63).
The public health treatment of substance use also intersects with leading causes of death in the US, chronic disease burdens, and health equity frameworks, since SUD prevalence, treatment access, and outcomes are unevenly distributed across racial, economic, and geographic lines. The full landscape of human health authority addresses these structural dimensions alongside clinical classifications.
References
- SAMHSA — Substance Abuse and Mental Health Services Administration
- NIDA — National Institute on Drug Abuse: Drugs, Brains, and Behavior: The Science of Addiction
- CDC — Alcohol-Related Disease Impact Application
- CDC — Smoking and Tobacco Use Fast Facts
- CDC — Drug Overdose Surveillance and Epidemiology
- [FDA — Drug Safety Communication: Risks of Combining Opioids and Benzodiazepines (2016)](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda